Table 5.
Trial | Study arms | Low risk | Intermediate risk | High risk | |||
---|---|---|---|---|---|---|---|
MMR | MR4.5 | MMR | MR4.5 | MMR | MR4.5 | ||
DASISION | Dasatinib (100 mg) | 90% | 55% | 71% | 43% | 67% | 31% |
Imatinib (400 mg) | 69% | 44% | 65% | 28% | 54% | 30% | |
ENESTnd | Nilotinib 300 mg twice daily | — | 53% | — | 60% | — | 45% |
Nilotinib 400 mg twice daily | — | 62% | — | 50% | — | 42% | |
Imatinib (400 mg) | — | 38% | — | 33% | — | 23% | |
BFORE | Bosutinib (400 mg) | 58% | — | 45% | — | 34% | — |
Imatinib (400 mg) | 46% | — | 39% | — | 17% | — |
The MMR and MR4.5 rates of these trials cannot be directly compared, because different methods of trial evaluation and different time points were presented in published data. For DASISION, MMR and MR4.5 are reported at any time with 5-year follow-up by Hasford (Euro) score. For ENESTnd, MMR and MR4.5 are rates are reported by 5-year by Sokal score. For BFORE, MMR rates are reported at 12 months by Sokal score.
MMR, major molecular response; MR, molecular response.